Fadraciclib is a pharmaceutical raw material under investigation as a CDK inhibitor. It is being studied in clinical trials for its potential role in targeting specific cyclin-dependent kinases.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1070790-89-4
Tosufloxacin monohydrate
pharmaceutical raw material
Perindopril erbumine
pharmaceutical raw material
Cevimeline hydrochloride
pharmaceutical raw material
Ixazomib
pharmaceutical raw material
(2R,3S)-3-[[6-[(4,6-dimethyl-3-pyridinyl)methylamino]-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol
DLPIYBKBHMZCJI-WBVHZDCISA-N
CC[C@@H]([C@@H](C)O)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CN=C(C=C3C)C